Loading...
Loading...
Pfizer
PFE announced today that a Phase 3 study of INLYTA
(axitinib) did not meet its primary endpoint of demonstrating
statistically significantly longer progression-free survival (PFS),
versus sorafenib, in treatment-naïve patients with advanced renal cell
carcinoma (RCC).
A preliminary review of the data showed that overall the median PFS for
INLYTA exceeded the median PFS for sorafenib, but did not meet
statistical significance. In a pre-specified subgroup of patients
classified as good Performance Status (ECOG PS 0), the median PFS for
INLYTA exceeded the median PFS for sorafenib. In another pre-specified
subgroup of patients classified as intermediate Performance Status (ECOG
PS 1), there was no difference between INLYTA and sorafenib.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in